期刊文献+

程序性死亡分子-1及其配体通路在眼科领域的研究进展 被引量:3

Research progress of programmed death-1 and its ligands pathway in ophthalmology
下载PDF
导出
摘要 共刺激信号已经成为免疫学研究的一个热点。程序性死亡分子-1(PD-1)及其配体属于抑制性共刺激分子,其在自身免疫性疾病、器官移植排斥反应、病原微生物感染、肿瘤免疫逃逸等方面都发挥着重要作用。近年来,PD—1及其配体(PD-1/PD—L)通路在眼科方面的研究也取得了一定进展。眼部多种疾病和现象,如眼部免疫性疾病、眼部感染性疾病、眼部肿瘤、眼组织的免疫赦免等均发现有PD—1/PD—L通路的改变。这些发现不仅进一步阐明了一些眼部疾病的发病机制,而且为其预防和治疗提供了新的方向。就PD—1/PD—L通路的生物学特性及其在眼科生理病理中的研究进展进行综述。 Costimulatory signals have become a hot field in immunological researches. As co-inhibitory molecules,programmed death-1 (PD-1) and its ligands (PD-1/PD-L) have been demonstrated to play an important role in autoimmune disease,organ transplant rejection,microorganism infection,tumor immune escapes etc.. In recent years,some studies about PD-1/PD-L pathway in ophthalmology have been curried out and reported. Some changes were found in PD-1/PD-L pathway, such as ocular immunologic diseases, ocular infectious diseases, ocular tumors, immune privilege in ocular tissues and so on. Through the research on PD-1/PD-L pathway, we can further understand the pathogenesis of some ocular diseases and find new methods for their prevention and treatments. This article reviewed the recent advances in PD-1/PD-L pathway in ophthalmological physiopathology.
出处 《中华实验眼科杂志》 CAS CSCD 北大核心 2011年第2期179-183,共5页 Chinese Journal Of Experimental Ophthalmology
基金 国家自然科学基金项目(30901653)、广东省科技计划项目(2008B030301178)通信作者:郭海科,Email:guohaike@medmail.com.cn
关键词 程序性死亡分子 配体 免疫调节 眼生理病理 PD-1 Ligand Immunoregulation Ophthalmological physiopathology
  • 相关文献

同被引文献37

  • 1Fong DS,Aiello L,Gardner TW,et al.Diabetic retinopathy[J].Diabetes care,2003,26:226-229.
  • 2The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J].N Engl J Med,1993,329:977-986.
  • 3UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)[J].Lancet,1998,352:854-865.
  • 4Sivenius K,Niskanen L,Voutilainen-Kaunisto R,et al.Aldose reduetase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes[J].Diabet Med,2004,21:1325-1333.
  • 5Sorbinil Retinopathy Trial Research Group.A randomized trial of sorbinil,an aldose reductase inhibitor,in diabetic retinopathy[J].Arch Ophthalmol,1990,108:1234-1244.
  • 6Sun W,Oates PJ,Coutcher JB,et al.A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy[J].Diabetes,2006,55:2757-2562.
  • 7Hammes HP,Du X,Edelstein D,et al.Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy[J].Nat Med,2003,9:294-309.
  • 8Zheng L,Szab6 C,Kern TS.Poly (ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB[J].Diabetes,2004,53:2960-2967.
  • 9Vlassara H.Recent progress in advanced glycation end products and diabetic complications[J].Diabetes,1997,46 Suppl 2:S19-25.
  • 10Kern TS,Engerman RL.Pharmacological inhibition of diabetic retinopathy:aminoguanidine and aspirin[J].Diabetes,2001,50:1636-1642.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部